← Leaderboards
Robert H Paul
Miriam Hospital
$19,178,842
Attributed
$27,335,467
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,335,467 · 12
By mechanism
R01$23,021,102 · 7
RF1$3,249,942 · 1
K23$728,363 · 1
R03$296,828 · 2
F32$39,232 · 1
Top collaborators
- Adam Wayne Carrico9 shared
- Victor Valcour5 shared
- Leah Helane Rubin4 shared
- Steven A Safren1 shared
- Serena S Spudich1 shared
Most similar at Miriam Hospital
Same institution · by research overlap
- Ronald A Cohen$16,764,338
- Joseph I Harwell$104,773
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainCognitiveCohortResearch PersonnelBaseCognitionAntiretroviral TherapyInvestigationEnrollmentFundingExhibitsIndexingAffectHiv InfectionsDiffusion Magnetic Resonance ImagingImpaired CognitionStructureNeuroimagingAcuteParticipantResponseBiologicalBrain RegionCognitive Therapy
Grant awards (45)
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1,007,048
R01 · FY2025 · MH
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1,062,625
R01 · FY2024 · MH
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1,095,679
R01 · FY2023 · MH
Mental Health and Cognition in HIV Infection in Rakai Uganda$578,547
R01 · FY2023 · MH
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1
R01 · FY2023 · MH
Longitudinal determination of nervous system consequences of SARS-CoV-2 in virologically suppressed people with HIV-1 treated in early infection$3,249,942
RF1 · FY2022 · MH
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1,039,095
R01 · FY2022 · MH
Mental Health and Cognition in HIV Infection in Rakai Uganda$566,935
R01 · FY2022 · MH
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)$1,218,576
R01 · FY2021 · MH
Viral and Host Determinants of Cognitive Status in Vertically Transmitted HIV$645,454
R01 · FY2021 · MH · contact PI
Enhancing Capacity for Mental Health Research and Care in Cambodia$602,382
R01 · FY2021 · MH · contact PI
Impact of Treatment on Brain Integrity in the Earliest Stages of HIV Infection$587,255
R01 · FY2021 · MH · contact PI
Mental Health and Cognition in HIV Infection in Rakai Uganda$583,619
R01 · FY2021 · MH
Viral and Host Determinants of Cognitive Status in Vertically Transmitted HIV$646,278
R01 · FY2020 · MH · contact PI
Enhancing Capacity for Mental Health Research and Care in Cambodia$618,916
R01 · FY2020 · MH · contact PI
Impact of Treatment on Brain Integrity in the Earliest Stages of HIV Infection$601,753
R01 · FY2020 · MH · contact PI
Mental Health and Cognition in HIV Infection in Rakai Uganda$580,077
R01 · FY2020 · MH
Viral and Host Determinants of Cognitive Status in Vertically Transmitted HIV$663,299
R01 · FY2019 · MH · contact PI
Enhancing Capacity for Mental Health Research and Care in Cambodia$633,013
R01 · FY2019 · MH · contact PI
Impact of Treatment on Brain Integrity in the Earliest Stages of HIV Infection$606,617
R01 · FY2019 · MH · contact PI
Viral and Host Determinants of Cognitive Status in Vertically Transmitted HIV$668,983
R01 · FY2018 · MH · contact PI
Enhancing Capacity for Mental Health Research and Care in Cambodia$667,815
R01 · FY2018 · MH · contact PI
Impact of Treatment on Brain Integrity in the Earliest Stages of HIV Infection$613,053
R01 · FY2018 · MH · contact PI
Viral and Host Determinants of Cognitive Status in Vertically Transmitted HIV$729,942
R01 · FY2017 · MH · contact PI
Enhancing Capacity for Mental Health Research and Care in Cambodia$684,007
R01 · FY2017 · MH · contact PI
Impact of Treatment on Brain Integrity in the Earliest Stages of HIV Infection$661,925
R01 · FY2017 · MH · contact PI
Neuropathogenesis of clade C HIV in South Africa$429,421
R01 · FY2013 · MH · contact PI
Neuropathogenesis of clade C HIV in South Africa$582,013
R01 · FY2012 · MH · contact PI
Neuropathogenesis of clade C HIV in South Africa$571,865
R01 · FY2011 · MH · contact PI
Neuromarkers of age-related cognitive decline$552,537
R01 · FY2011 · NS · contact PI
Neuropathogenesis of clade C HIV in South Africa$628,320
R01 · FY2010 · MH · contact PI
Neuromarkers of age-related cognitive decline$541,713
R01 · FY2010 · NS · contact PI
Neuropathogenesis of clade C HIV in South Africa$727,877
R01 · FY2009 · MH · contact PI
Neuromarkers of age-related cognitive decline$541,289
R01 · FY2009 · NS · contact PI
Neuromarkers of age-related cognitive decline$506,455
R01 · FY2008 · NS · contact PI
Neuromarkers of age-related cognitive decline$576,718
R01 · FY2007 · NS · contact PI
Functional Neuroimaging of Cognitive Dysfunction in HIV-HCV Co-Infection$226,500
R03 · FY2006 · DA · contact PI
Improving adherence to HAART in HIV$152,024
K23 · FY2006 · MH · contact PI
Improving adherence to HAART in HIV$127,117
K23 · FY2005 · MH
Improving adherence to HAART in HIV$21,791
K23 · FY2005 · MH
Improving adherence to HAART in HIV$146,135
K23 · FY2004 · MH
Improving adherence to HAART in HIV$143,361
K23 · FY2003 · MH
Improving adherence to HAART in HIV$137,935
K23 · FY2002 · MH
Cognition in HIV-infected cocaine abusers$70,328
R03 · FY2001 · DA
COGNITION, FATIGUE, AND MOOD IN MYASTHENIA GRAVIS$39,232
F32 · FY2000 · NS